Add 2 More Reports For 20% off

Report Overview

Breast cancer marks an abnormal breast cell growth that results in tumor development. According to the Wor ld Health Organization, breast cancer was the most common cancer in women in 2022. Around 2.3 million women were diagnosed with breast cancer and 670 000 deaths were registered in 2022. To tackle the rising mortality rates, various companies are committed to develop new breast cancer drug candidates across the region.

Report Coverage

The Breast Cancer Drug Pipeline report by Expert Market Research gives comprehensive insights on the breast cancer therapeutic drugs currently undergoing clinical trials. It covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on breast cancer pipeline landscape.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to breast cancer are covered. Moreover, breast cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Breast Cancer Drug Pipeline Outlook

Breast cancer begins inside the milk ducts of the breast, when the cells undergo continuous multiplication, leading to occurrence of a tumor. These tumors can cause lumps or thickening and can be considered as the early signs of detection. Although the in-situ form is not life-threatening and can be detected at early stages, the global estimates demonstrate large inequities in the breast cancer burden. For instance, 1 in 12 women will be diagnosed with breast cancer in their lifetime in countries with a very high human development index (HDI). 

Early signs of breast cancer include changes in the shape and size of the breast, redness, scaling, dimpling, or puckering in the skin, swelling, or a lump near or in the breast or underarm area. Common breast cancer screening tests include clinical breast exam, ultrasound, mammogram, MRI, and biopsy. Various types of breast cancer treatments and medication classes, including targeted therapies, immunotherapies, biosimilars, are available to treat different types of breast cancer. Surgery, chemotherapy, radiation, targeted therapy, hormone therapy, and immunotherapy are amongst standard treatments used for breast cancer.

Currently, several clinical trials are in progress to develop effective treatment alternatives for breast cancer, indicating a promising future for the treatment landscape. Some of the notable breast cancer drug candidates which are showing promising results in breast cancer treatment include PI3K/mTOR inhibitors, TROP2-directed antibody-drug conjugates (ADC), and a first-in-human trial assessing a cancer-killing oncolytic virus.

The American Society for Clinical Oncology (ASCO) Annual Meeting 2022 featured important presentations. In August 2022, the United States FDA approved fam-trastuzumab deruxtecan-nxki by Daiichi Sankyo Co, Ltd., for the treatment of patients with unresectable or HER2+ metastatic breast cancer. The drug is intended for patients who have received a prior anti–HER2-based regimen. Other notable approval was Olaparib developed by AstraZeneca. The drug is used for the treatment of adult patients with suspected deleterious germline BRCA-mutated HER2–high-risk early breast cancer.

The breast cancer pipeline insight covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials cancer in detail.

Breast Cancer – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of breast cancer drug candidates based on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analysis based on phase.

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Route of Administration

EMR’s breast cancer therapeutic assessment report covers 50+ drug analysis based on route of administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Breast Cancer – Pipeline Assessment Segmentation, By Phases

The breast cancer pipeline analysis covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in-depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover a major share of the total breast cancer clinical trials conducted.

DS-8201a is amongst notable phase II drugs, currently being developed by UNICANCER. The study is conducted to assess the efficacy of DS-8201a monotherapy in patients suffering from metastatic breast cancer.

Breast Cancer – Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under breast cancer pipeline report include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route accounted for the major share of breast cancer clinical trials.

Breast Cancer Clinical Trials Assessment – Competitive Dynamics

The EMR report for breast cancer drug pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed breast cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of few players involved in breast cancer clinical trials:

  • AstraZeneca
  • Daiichi Sankyo Co., Ltd.
  • GlaxoSmithKline
  • Bayer AG
  • F. Hoffmann-La Roche
  • Novartis Pharmaceuticals
  • Seagen Inc.
  • Pfizer, Inc.
  • Merck KGaA
  • Others

Breast Cancer – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. Moreover, the section covers include product description, trial ID, study type, drug class, mode of administration, and recruitment status of breast cancer clinical trial drugs.

Inavolisib - Hoffmann-La Roche

Inavolisib is currently under phase III, sponsored by Hoffmann-La Roche. The study is being done to assess the safety and efficacy of Phesgo (trastuzumab, pertuzumab, and rHuPH20 injection) in participants with previously untreated HER2-positive advanced breast cancer.

Drug: Sagopilone – Bayer AG

Sagopilone is currently under phase II, sponsored by Bayer AG. The purpose of the study is to evalua...

Drug: DS-8201a - Daiichi Sanky o Co., Ltd.

Developed by Daiichi Sankyo Co., Ltd., the drug is currently under phase II. The study is conducted ...

Drug: Sacituzumab Tirumotecan - Merck KGaA

This drug is currently under phase III and is developed by Merck KGaA. It is being studied to compar...

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Key Questions Answered in the Breast Cancer – Pipeline Assessment Report

  • What is the current landscape of breast cancer pipeline drugs?
  • Which companies/institutions are developing breast cancer therapeutic drugs?
  • How many phase II drugs are currently present in breast cancer pipeline drugs?
  • Which company is leading the breast cancer pipeline development activities?
  • What is the current breast cancer commercial assessment?
  • What are the opportunities and challenges present in the breast cancer drug pipeline landscape?
  • What is the efficacy and safety profile of breast cancer pipeline drugs?
  • Which companies/institutions are involved in breast cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in breast cancer?

Related Reports

Global Breast Cancer Therapeutics Market

Global Breast Cancer Treatment Market

Global Breast Implants Market

Global Digital Breast Tomosynthesis Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report Details
Drug Pipeline by Clinical Trial Phase
  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products 
Route of Administration
  • Oral
  • Intravenous 
  • Subcutaneous
  • Parenteral
  • Topical
Drug Classes
  • Small Molecule
  • Polymer
  • Monoclonal Antibody
  • Peptides
  • Gene Therapy
Treatment Type
  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Others
Leading Sponsors Covered
  • AstraZeneca
  • Daiichi Sankyo Co., Ltd.
  • GlaxoSmithKline
  • Bayer AG
  • F. Hoffmann-La Roche
  • Novartis Pharmaceuticals
  • Seagen Inc.
  • Pfizer, Inc.
  • Merck KGaA
  • Others
Geographies Covered
  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124